ICU Medical (ICUI) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for ICU Medical (ICUI) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
For the quarter ended June 2026, ICU Medical (ICUI) reported revenue of $547.88 million, up 0.8% over the same period last year. EPS came in at $2.37, compared to $2.10 in the year-ago quarter.
The reported revenue represents a surprise of +2.33% over the Zacks Consensus Estimate of $535.43 million. With the consensus EPS estimate being $1.91, the EPS surprise was +24.08%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how ICU Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Infusion Systems: $189 million compared to the $177.16 million average estimate based on two analysts.
- Revenue- Vital Care: $73.41 million versus the two-analyst average estimate of $74.03 million.
- Revenue- Consumables: $289.28 million versus the two-analyst average estimate of $288.89 million.
View all Key Company Metrics for ICU Medical here>>>
Shares of ICU Medical have returned +9.6% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ICU Medical, Inc. (ICUI): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).